MedTrace Logo

miRNAs and mRNAs in Psoriasis

NCT01604902 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2014-08-25

No results posted yet for this study

Summary

PURPOSE - The purpose of this study is to identify and determine miRNA expression and their targets before and during biological treatment of psoriatic patients.

HYPOTHESIS - Changes in the expression of specific miRNAs play an important role for the cytokine expression profile seen in lesional psoriatic skin. miRNAs may therefore serve as a potential target for future anti-psoriatic treatment as well as possible predictors of biological treatment response.

PERSPECTIVES - The results from this novel research project will increase the investigators understanding of the underlying mechanisms leading to psoriasis. Furthermore it is possible that predictors of treatment response can be identified. Identification of biomarkers predicting treatment outcome will individualize patient care, reduce number of treatment failures and thereby have a tremendous socio-economic impact and increase the patients quality of life.

Conditions

Interventions

OTHER

4 mm punch biopsies

4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Aage Bangs Fond

    collaborator OTHER

  • Aase and Ejnar Danielsens Foundation

    collaborator OTHER

  • Direktør Jacob Madsens Og Hustru Olga Madsens Fond

    collaborator UNKNOWN

  • Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Line R OIsen, MD · Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-03-31
Completion
2016-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01604902 on ClinicalTrials.gov